Reimpresión oficial de UpToDate ®

www.uptodate.com © 2022 UpToDate, Inc. y/o sus afiliados. Todos los derechos reservados.

Uso de vasopresores e inotrópicos

Autor: Scott Manager, MD, PhD
Redactor de sección: Polly E Parsons, MD
Redactor adjunto: Dra. Geraldine Finlay

Todos los temas se actualizan a medida que se dispone de nueva evidencia y se completa nuestro proceso de
revisión por pares .

Revisión de la literatura actual hasta:  febrero de 2022. | Última actualización de este tema:  15 de marzo
de 2022.

INTRODUCCIÓN

Los vasopresores son una poderosa clase de fármacos que inducen la vasoconstricción y,
por lo tanto, elevan la presión arterial media (PAM). Los vasopresores difieren de los
inotrópicos, que aumentan la contractilidad cardíaca; sin embargo, muchos fármacos tienen
efectos tanto vasopresores como inotrópicos. Aunque se han usado muchos vasopresores
desde la década de 1940, pocos ensayos clínicos controlados compararon directamente
estos agentes o documentaron mejores resultados debido a su uso [ 1 ]. Por lo tanto, la
forma en que estos agentes se usan comúnmente refleja en gran medida la opinión de los
expertos, los datos de animales y el uso de criterios de valoración alternativos, como la
oxigenación tisular, como indicador de la disminución de la morbilidad y la mortalidad.

Aquí se presentan la fisiología básica de los receptores adrenérgicos y los principios,

complicaciones y controversias que rodean el uso de vasopresores e inotrópicos para el
tratamiento del shock. Los temas relacionados con el diagnóstico diferencial de shock y el
uso de vasopresores en pacientes con shock séptico se discuten por separado. (Ver
"Definición, clasificación, etiología y fisiopatología del shock en adultos" y "Evaluación y
manejo de sospecha de sepsis y shock séptico en adultos" .)

MECANISMOS FISIOLÓGICOS DE LA VASOCONSTRICCIÓN

Las principales categorías de receptores adrenérgicos relevantes para la actividad

vasopresora son los receptores adrenérgicos alfa-1, beta-1 y beta-2, así como los receptores
de dopamina [ 2,3 ].
Alfa adrenérgico  :  la activación de los receptores alfa-1 adrenérgicos, ubicados en las
paredes vasculares, induce una vasoconstricción significativa. Los receptores adrenérgicos
alfa-1 también están presentes en el corazón y pueden aumentar la duración de la
contracción sin aumentar la cronotropía. Sin embargo, la importancia clínica de este
fenómeno no está clara [ 4 ].

Beta adrenérgicos  :  los receptores adrenérgicos beta-1 son más comunes en el corazón y
median aumentos en la inotropía y la cronotropía con una vasoconstricción mínima. La
estimulación de los receptores adrenérgicos beta-2 en los vasos sanguíneos induce la
vasodilatación.

Dopamina  :  los receptores de dopamina están presentes en los lechos vasculares renal,
esplácnico (mesentérico), coronario y cerebral; la estimulación de estos receptores conduce
a la vasodilatación. Un segundo subtipo de receptores de dopamina provoca
vasoconstricción al inducir la liberación de norepinefrina .

Sensibilizantes de calcio  :  algunos agentes aumentan la sensibilidad del aparato contráctil
del miocardio al calcio, lo que provoca un aumento en el desarrollo de la tensión del
miofilamento y la contractilidad del miocardio (p. ej., pimobendan, levosimendan). Estos
agentes tienen propiedades farmacológicas adicionales, como la inhibición de la
fosfodiesterasa, que pueden aumentar la inotropía y la vasodilatación y contribuir
significativamente a su perfil clínico, cuyos detalles se analizan por separado.

Angiotensina  :  los receptores de angiotensina (AT 1 y AT 2 ) son receptores de proteínas

acopladas a G con angiotensina II como ligando. La angiotensina II es un vasoconstrictor
que forma parte del sistema renina-aldosterona-angiotensina (SRAA). Cuando se estimulan
los receptores, la concentración de calcio citosólico aumenta para mediar los efectos
vasoconstrictores, así como la secreción de aldosterona y vasopresina [ 5 ].

PRINCIPIOS

Hypotension may result from hypovolemia (eg, exsanguination), pump failure (eg, severe
medically refractory heart failure or shock complicating myocardial infarction), or a
pathologic maldistribution of blood flow (eg, septic shock, anaphylaxis). (See "Definition,
classification, etiology, and pathophysiology of shock in adults" and "Inotropic agents in
heart failure with reduced ejection fraction".)

Vasopressors are indicated for a decrease of >30 mmHg from baseline systolic blood
pressure, or a mean arterial pressure <60 mmHg when either condition results in end-organ
dysfunction due to hypoperfusion. Hypovolemia should be corrected prior to the institution
of vasopressor therapy [6]. (See "Treatment of severe hypovolemia or hypovolemic shock in
adults".)

The rational use of vasopressors and inotropes is guided by three fundamental concepts:

● One drug, many receptors – A given drug often has multiple effects because of actions
upon more than one receptor. As an example, dobutamine increases cardiac output by
beta-1 adrenergic receptor activation; however, it also acts upon beta-2 adrenergic
receptors and thus induces vasodilation and can cause hypotension.

● Dose-response curve – Many agents have dose-response curves, such that the primary
adrenergic receptor subtype activated by the drug is dose-dependent. As an example,
dopamine stimulates beta-1 adrenergic receptors at doses of 2 to 10 mcg/kg per
minute, and alpha adrenergic receptors when doses exceed 10 mcg/kg per minute.

● Direct versus reflex actions – A given agent can affect mean arterial pressure (MAP)
both by direct actions on adrenergic receptors and by reflex actions triggered by the
pharmacologic response. Norepinephrine-induced beta-1 adrenergic stimulation alone
normally would cause tachycardia. However, the elevated MAP from norepinephrine's
alpha-adrenergic receptor-induced vasoconstriction results in a reflex decrease in heart
rate. The net result may be a stable or slightly reduced heart rate when the drug is
used.

PRACTICAL ISSUES

Use of vasopressors and inotropic agents requires attention to a number of issues:

Volume resuscitation — Adequate intravascular volume resuscitation, when time permits,

is crucial prior to the initiation of vasopressors. As an example, most patients with septic
shock require at least 2 liters of intravenous fluid in order for vasopressors to be maximally
effective [7]. Vasopressors will be ineffective or only partially effective in the setting of
coexistent hypovolemia.

Fluids may be withheld in patients with significant pulmonary edema due to the acute
respiratory distress syndrome (ARDS) or heart failure (HF). In patients with a pulmonary
artery catheter, pulmonary capillary wedge pressures (PCWP) of 18 to 24 mmHg are
recommended for cardiogenic shock [8], and 12 to 14 mmHg for septic or hypovolemic shock
[9]. (See "Pulmonary artery catheterization: Interpretation of hemodynamic values and
waveforms in adults".)

Selection and titration — Choice of an initial agent should be based upon the suspected
underlying etiology of shock (eg, dobutamine in cases of cardiac failure without significant
hypotension, epinephrine for anaphylactic shock). The dose should be titrated up to achieve
effective blood pressure or end-organ perfusion as evidenced by such criteria as urine
output or mentation. If maximal doses of a first agent are inadequate, then a second drug
should be added to the first. In situations where this is ineffective, such as refractory septic
shock, anecdotal reports describe adding a third agent, although no controlled trials have
demonstrated the utility of this approach.

Route of administration — Vasopressors and inotropic agents should be administered

through an appropriately positioned central venous catheter, if available. This facilitates
more rapid delivery of the agent to the heart for systemic distribution and eliminates the risk
of peripheral extravasation. When a patient does not have a central venous catheter,
vasopressors and inotropic agents can be administered through an appropriately positioned
peripheral intravenous catheter temporarily, until a central venous catheter is inserted
[10,11]. (See "Overview of complications of central venous catheters and their prevention in
adults" and "Overview of central venous access in adults".)

Tachyphylaxis — Responsiveness to these drugs can decrease over time due to

tachyphylaxis. Doses must be constantly titrated to adjust for this phenomenon and for
changes in the patient's clinical condition [12,13].

Hemodynamic effects — Mean arterial pressure (MAP) is influenced by systemic vascular

resistance (SVR) and cardiac output (CO). In situations such as cardiogenic shock, elevating
SVR increases afterload and the work of an already failing heart, thus potentially lowering
CO. Some authors recommend keeping the SVR approximately 700 to 1000 dynes x sec/cm5
to avoid excessive afterload and to minimize complications from profound vasoconstriction
(calculator 1) [14]. However, there is no consensus regarding an ideal target cardiac index
(CI). Studies that have attempted to maintain a supraphysiologic CI of >4 to 4.5 L/minute per
m2 have not shown consistent benefit [15,16]. (See "Oxygen delivery and consumption".)

Subcutaneous delivery of medications — Critically ill patients often receive subcutaneously

injected medications, such as heparin and insulin. The bioavailability of these medications
can be reduced during treatment with vasopressors due to cutaneous vasoconstriction.

This was demonstrated in a study that monitored plasma factor Xa levels in three groups of
hospitalized patients following the initiation of prophylactic low molecular weight
heparin [17]. Patients who required vasopressor support (dopamine >10 mcg/kg per minute,
norepinephrine >0.25 mcg/kg per minute, or phenylephrine >2 mcg/kg per minute) had
decreased factor Xa activity compared to both intensive care unit (ICU) patients who did not
require vasopressors and routine postoperative control patients. The clinical significance of
the decrease in plasma factor Xa levels was not determined.
The authors of the study suggested that patients might need higher doses of LMW heparin
to attain adequate thrombosis prophylaxis. Another approach is to change subcutaneous
medications to an intravenous form whenever a patient is receiving vasopressor therapy.

Frequent re-evaluation — Critically ill patients may undergo a second hemodynamic insult

which necessitates a change in vasopressor or inotrope management. The dosage of a given
agent should not simply be increased because of persistent or worsening hypotension
without reconsideration of the patient's clinical situation and the appropriateness of the
current strategy.

ADRENERGIC AGENTS

Adrenergic agents, such as phenylephrine, norepinephrine, dopamine, and dobutamine, are

the most commonly used vasopressor and inotropic drugs in critically ill patients ( table 1).
These agents manifest different receptor selectivity and clinical effects ( table 2).

Norepinephrine — Norepinephrine (Levophed) acts on both alpha-1 and beta-1 adrenergic

receptors, thus producing potent vasoconstriction as well as a modest increase in cardiac
output [6]. A reflex bradycardia usually occurs in response to the increased mean arterial
pressure (MAP), such that the mild chronotropic effect is canceled out and the heart rate
remains unchanged or even decreases slightly. Norepinephrine is the preferred vasopressor
for the treatment of septic shock. (See 'Choice of agent in septic shock' below and
"Evaluation and management of suspected sepsis and septic shock in adults".)

Phenylephrine — Phenylephrine (Neo-Synephrine) has purely alpha-adrenergic agonist

activity and therefore results in vasoconstriction with minimal cardiac inotropy or
chronotropy. MAP is augmented by raising systemic vascular resistance (SVR) [18]. The drug
is useful in the setting of hypotension with an SVR <700 dynes x sec/cm5 (eg, hyperdynamic
sepsis, neurologic disorders, anesthesia-induced hypotension). A potential disadvantage of
phenylephrine is that it may decrease stroke volume, so it is reserved for patients in whom
norepinephrine is contraindicated due to arrhythmias or who have failed other therapies.

Although SVR elevation increases cardiac afterload, most studies document that cardiac
output (CO) is either maintained or actually increased among patients without pre-existing
cardiac dysfunction [4,19]. The drug is contraindicated if the SVR is >1200 dynes x sec/cm5.

Epinephrine — Epinephrine (Adrenalin) has potent beta-1 adrenergic receptor activity and

moderate beta-2 and alpha-1 adrenergic receptor effects. Clinically, low doses of epinephrine
increase CO because of the beta-1 adrenergic receptor inotropic and chronotropic effects,
while the alpha adrenergic receptor-induced vasoconstriction is often offset by the beta-2
adrenergic receptor vasodilation. The result is an increased CO, with decreased SVR and
variable effects on the MAP [3].However, at higher epinephrine doses the alpha-adrenergic
receptor effect predominates, producing increased SVR in addition to an increased CO.
Epinephrine is most often used for the treatment of anaphylaxis, as a second line agent
(after norepinephrine) in septic shock, and for management of hypotension following
coronary artery bypass grafting.

Other disadvantages of epinephrine include dysrhythmias (due to beta-1 adrenergic

receptor stimulation) and splanchnic vasoconstriction. The degree of splanchnic
vasoconstriction appears to be greater with epinephrine than with equipotent doses of
norepinephrine or dopamine in patients with severe shock [20], although the clinical
importance of this is unclear.

Ephedrine — Similar to epinephrine, ephedrine acts primarily on alpha- and beta-adrenergic

receptors, but with less potency. It also has an effect by leading to release of endogenous
norepinephrine. Ephedrine is rarely used except in the setting of post-anesthesia-induced
hypotension.

Dopamine — Dopamine (Intropin) has a variety of effects depending upon the dose range
administered. It is most often used as a second-line alternative to norepinephrine in patients
with absolute or relative bradycardia and a low risk of tachyarrhythmias. Weight-based
administration of dopamine can achieve quite different serum drug concentrations in
different individuals [21], but the following provides an approximate description of effects:

● At doses of 1 to 2 mcg/kg per minute, dopamine acts predominantly on dopamine-1

receptors in the renal, mesenteric, cerebral, and coronary beds, resulting in selective
vasodilation. Some reports suggest that dopamine increases urine output by
augmenting renal blood flow and glomerular filtration rate, and natriuresis by
inhibiting aldosterone and renal tubular sodium transport [22-24]. These effects may
be blunted by haloperidol and other butyrophenones [24]. However, the clinical
significance of these phenomena is unclear, and some patients may develop
hypotension at these low doses [25]. (See "Renal actions of dopamine".)

● At 5 to 10 mcg/kg per minute, dopamine also stimulates beta-1 adrenergic receptors

and increases cardiac output, predominantly by increasing stroke volume with variable
effects on heart rate [26]. Doses between 2 and 5 mcg/kg per minute have variable
effects on hemodynamics in individual patients: vasodilation is often balanced by
increased stroke volume, producing little net effect upon systemic blood pressure.
Some mild alpha adrenergic receptor activation increases SVR, and the sum of these
effects is an increase in MAP.

● At doses >10 mcg/kg per minute, the predominant effect of dopamine is to stimulate
alpha-adrenergic receptors and produce vasoconstriction with an increased SVR
 [26,27]. However, the overall alpha-adrenergic receptor effect of dopamine is weaker
than that of norepinephrine, and the beta-1 adrenergic receptor stimulation of
dopamine at doses >2 mcg/kg per minute can result in dose-limiting dysrhythmias.

In practical terms, the dose-dependent effects of dopamine mean that changing the dose of
the drug is akin to switching vasopressors. Conversely, simply increasing the dose of
dopamine without being cognizant of the different receptor populations activated can cause
untoward results.

The usual dose range for dopamine is 2 to 20 mcg/kg per minute, although doses as high as
130 mcg/kg per minute have been employed [28]. When used for cardiac failure, dopamine
should be started at 2 mcg/kg per minute and then titrated to a desired physiologic effect
rather than depending on the predicted pharmacologic ranges described above.

Dobutamine — Dobutamine (Dobutrex) is not a vasopressor but rather is an inotrope that

causes vasodilation. Dobutamine's predominant beta-1 adrenergic receptor effect increases
inotropy and chronotropy and reduces left ventricular filling pressure. In patients with heart
failure this results in a reduction in cardiac sympathetic activity [29]. However, minimal
alpha- and beta-2 adrenergic receptor effects result in overall vasodilation, complemented
by reflex vasodilation to the increased CO. The net effect is increased CO, with decreased SVR
with or without a small reduction in blood pressure.

Dobutamine is most frequently used in severe, medically refractory heart failure and
cardiogenic shock and should not be routinely used in sepsis because of the risk of
hypotension. Dobutamine does not selectively vasodilate the renal vascular bed, as
dopamine does at low doses. (See "Inotropic agents in heart failure with reduced ejection
fraction".)

Isoproterenol — Isoproterenol (Isuprel) also is primarily an inotropic and chronotropic

agent rather than a vasopressor. It acts upon beta-1 adrenergic receptors and, unlike
dobutamine, has a prominent chronotropic effect. The drug's high affinity for the beta-2
adrenergic receptor causes vasodilation and a decrease in MAP. Therefore, its utility in
hypotensive patients is limited to situations in which hypotension results from bradycardia.

Contraindications and interactions — Several conditions or medications require avoidance

of specific agents:

● In patients with cardiogenic shock, norepinephrine is preferred over dopamine as the

first-line vasopressor because a subgroup analysis from a randomized trial found that
patients with cardiogenic shock who received dopamine had a higher mortality than
those who received norepinephrine [30]. In addition, dysrhythmias were more common
in the dopamine group.
 ● Patients with pheochromocytoma are at risk of excessive autonomic stimulation from
adrenergic vasopressors.

● Dobutamine is contraindicated in the setting of idiopathic hypertrophic subaortic

stenosis.

● Patients receiving monoamine oxidase inhibitors are extremely sensitive to

vasopressors and, therefore, require much lower doses.

VASOPRESSIN AND ANALOGS

Vasopressin (antidiuretic hormone) is used in the management of diabetes insipidus and

esophageal variceal bleeding; however, it may also be helpful in the management of
vasodilatory shock ( table 1). Although its precise role in vasodilatory shock remains to be
defined, it is primarily used as a second-line agent in refractory vasodilatory shock,
particularly septic shock or anaphylaxis that is unresponsive to epinephrine [31-37]. It is also
used occasionally to reduce the dose of the first-line agent. Terlipressin, a vasopressin
analog, has been assessed in patients with vasodilatory shock [38-43], but it is not available
in the United States.

The effects of vasopressin and terlipressin in vasodilatory shock (mostly septic shock) were
evaluated in a systematic review that identified 10 relevant randomized trials (1134 patients)
[44]. A meta-analysis of six of the trials (512 patients) compared vasopressin or terlipressin
with placebo or supportive care. There was no significant improvement in short-term
mortality among patients who received either vasopressin or terlipressin (40.2 versus 42.9
percent, relative risk 0.91, 95% CI 0.79-1.05). However, patients who received vasopressin or
terlipressin required less norepinephrine. A second randomized trial compared vasopressin
with norepinephrine in 409 patients with septic shock. Although vasopressin did not improve
mortality or the number of kidney failure-free days, it may have been associated with a
reduction in the rate of kidney failure requiring renal replacement therapy (25 versus 35
percent) [45]. Further studies are needed before vasopressin can replace norepinephrine as
the first-choice agent for those with septic shock. (See 'Choice of agent in septic shock'
below.)

The effects of vasopressin may be dose dependent. A randomized trial compared two doses
of vasopressin (0.0333 versus 0.067 IU/min) in 50 patients with vasodilatory shock who
required vasopressin as a second pressor agent [46]. The higher dose was more effective at
increasing the blood pressure without increasing the frequency of adverse effects in these
patients. However, doses of vasopressin above 0.04 units/min have been associated with
coronary and mesenteric ischemia and skin necrosis in some studies [47-50], although some
of these studies were in animals and necrosis in humans may also have been due to
coexisting conditions (eg, disseminated intravascular coagulation). However, doses higher
than the therapeutic range (0.04 units/min) are generally avoided for this reason unless an
adequate mean arterial pressure (MAP) cannot be attained with other vasopressor agents.
When weaning, we generally attempt to wean off vasopressin before norepinephrine.

Based upon clinical experience, hypotension appears to be common following withdrawal of

vasopressin. To avoid this, the dose can be slowly tapered by 0.01 units/minute every 30 to
60 minutes [51,52].

Other potential adverse effects of vasopressin include hyponatremia, pulmonary

vasoconstriction, and diabetes insipidus [47-50,53]. Terlipressin appears to have a similar
side effect profile to vasopressin. In a meta-analysis of four trials (431 patients) that was
conducted as part of the systematic review described above, there was no significant
difference in the frequency of adverse events among patients who received either
vasopressin or terlipressin (10.6 versus 11.8 percent, relative risk 0.90, 95% CI 0.49-1.67) [44].

NONADRENERGIC AGENTS

A number of agents produce vasoconstriction or inotropy through nonadrenergic

mechanisms, including phosphodiesterase inhibitors and nitric oxide synthase inhibitors,
calcium sensitizers, or angiotensin II.

PDE inhibitors — Phosphodiesterase (PDE) inhibitors, such as inamrinone (formerly known

as amrinone) and milrinone, are nonadrenergic drugs with inotropic and vasodilatory
actions. In many ways, their effects are similar to those of dobutamine but with a lower
incidence of dysrhythmias. PDE inhibitors most often are used to treat patients with
impaired cardiac function and medically refractory heart failure, but their vasodilatory
properties limit their use in hypotensive patients [26]. Inamrinone is no longer available in
North America and most/all other countries so the only intravenous PDE inhibitor used in the
US is milrinone. (See "Inotropic agents in heart failure with reduced ejection fraction".)

NOS inhibitors — Nitric oxide overproduction appears to play a major role in vasodilation

induced by sepsis (see "Pathophysiology of sepsis"). Studies of nitric oxide synthase (NOS)
inhibitors such as N-monomethyl-L-arginine (L-NMMA) in sepsis demonstrate a dose-
dependent increase in systemic vascular resistance (SVR) [54]. However, cardiac index (CI)
and heart rate (HR) decrease, even when patients are treated concomitantly with
norepinephrine or epinephrine. The increase in SVR tends to be offset by the drop in CI, such
that mean arterial pressure (MAP) is only minimally augmented. The clinical utility of this
class of drugs remains unproven.
Calcium sensitizers — Several agents increase myocardial contractility (eg, pimobendan,
levosimendan) but conclusive evidence of improved outcomes with their use is lacking
[55,56].

Angiotensin II — Preliminary trials have reported an adequate vasopressor effect when

synthetic angiotensin II is exogenously administered for vasodilatory shock (eg, septic shock)
[57,58]. Best supporting its role as a vasopressor agent is a randomized trial of 344 patients
with vasodilatory shock (80 percent had sepsis and patients had a normal cardiac output)
already receiving high dose norepinephrine or similar vasopressor equivalent [59]. When
compared with placebo, angiotensin II resulted in a greater proportion of patients achieving
a 10 mmHg or greater increase in the baseline mean arterial pressure (MAP) or more or an
increase in the MAP to 75 mmHg or higher (70 versus 23 percent), at three hours. There was
no effect on mortality or on the sequential organ failure assessment score. Serious adverse
events were no different among the groups. Angiotensin II resulted in less background
vasopressor use and higher heart rates but did not result in life-threatening
tachyarrhythmias. Further trials will be required to compare angiotensin II with other
vasopressor agents and to examine its effects in populations other than those with
vasodilatory shock before it can be routinely used as a second line agent for the treatment of
shock.

COMPLICATIONS

Vasopressors and inotropic agents have the potential to cause a number of significant
complications, including hypoperfusion, dysrhythmias, myocardial ischemia, local effects,
and hyperglycemia. In addition, a number of drug interactions exist.

Hypoperfusion — Excessive vasoconstriction in response to hypotension and vasopressors

can produce inadequate perfusion of the extremities, mesenteric organs, or kidneys.
Excessive vasoconstriction with inadequate perfusion, usually with an systemic vascular
resistance (SVR) >1300 dynes x sec/cm5, commonly occurs in the setting of inadequate
cardiac output or inadequate volume resuscitation.

The initial findings are dusky skin changes at the tips of the fingers and/or toes, which may
progress to frank necrosis with autoamputation of the digits. Compromise of the renal
vascular bed may produce renal insufficiency and oliguria, while patients with underlying
peripheral artery disease may develop acute limb ischemia.

Inadequate mesenteric perfusion increases the risk of gastritis, shock liver, intestinal
ischemia, or translocation of gut flora with resultant bacteremia. Despite these concerns,
maintenance of MAP with vasopressors appears more effective in maintaining renal and
mesenteric blood flow than allowing the MAP to drop, and maintenance of MAP with
vasopressors may be life-saving despite evidence of localized hypoperfusion [18,60].

Dysrhythmias — Many vasopressors and inotropes exert powerful chronotropic effects via

stimulation of beta-1 adrenergic receptors. This increases the risk of sinus tachycardia (most
common), atrial fibrillation (potentially with increased atrioventricular nodal [A-V] conduction
and therefore an increased ventricular response), re-entrant atrioventricular node
tachycardia, or ventricular tachyarrhythmias.

Adequate volume loading may minimize the frequency or severity of dysrhythmias. Despite
this, dysrhythmias often limit the dose and necessitate switching to another agent with less
prominent beta-1 effects. The degree to which the agent affects the frequency of
dysrhythmias was illustrated by a randomized trial of 1679 patients with shock [30].
Dysrhythmias were significantly more common among patients who received dopamine
than among those who received norepinephrine (24.1 versus 12.4 percent).

Myocardial ischemia — The chronotropic and inotropic effects of beta-adrenergic receptor

stimulation can increase myocardial oxygen consumption. While there is usually coronary
vasodilation in response to vasopressors [61], perfusion may still be inadequate to
accommodate the increased myocardial oxygen demand. Daily electrocardiograms on
patients treated with vasopressors or inotropes may screen for occult ischemia, and
excessive tachycardia should be avoided because of impaired diastolic filling of the coronary
arteries.

Local effects — Peripheral extravasation of vasopressors into the surrounding connective

tissue can lead to excessive local vasoconstriction with subsequent skin necrosis. To avoid
this complication, vasopressors should be administered via a central vein whenever possible.
If infiltration occurs, local treatment with phentolamine (5 to 10 mg in 10 mL of normal
saline) injected subcutaneously can minimize local vasoconstriction [62].

Hyperglycemia — Hyperglycemia may occur due to the inhibition of insulin secretion. The

magnitude of hyperglycemia generally is minor and is more pronounced with
norepinephrine and epinephrine than dopamine [23]. Monitoring of blood glucose while on
vasopressors can prevent complications of untreated hyperglycemia.

CONTROVERSIES

Several controversies exist regarding the use of vasopressors and inotropic agents in
critically ill patients. Most stem from the relative paucity of large-scale studies comparing
similar patient populations treated with different regimens. The development of clear
definitions for the systemic inflammatory response syndrome, sepsis, and septic shock is a
step forward toward comparative trials among standardized patient populations. (See
"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and
prognosis".)

Choice of agent in septic shock — The optimal agent in patients with septic shock is
unknown and practice varies considerably among experts. However, based upon meta-
analyses of small randomized trials and observational studies, a paradigm shift in practice
has occurred such that most experts prefer to avoid dopamine in this population and favor
norepinephrine as the first-choice agent the details of which are discussed separately. (See
"Evaluation and management of suspected sepsis and septic shock in adults", section on
'Vasopressors'.)

"Renal dose" dopamine — Dopamine selectively increases renal blood flow when

administered to normal volunteers at 1 to 3 mcg/kg per minute [63,64]. Animal studies also
suggest that low-dose dopamine in the setting of vasopressor-dependent sepsis helps
preserve renal blood flow [65]. (See "Renal actions of dopamine" and "Possible prevention
and therapy of ischemic acute tubular necrosis".)

However, a beneficial effect of low or "renal dose" dopamine is less proven in human
patients with sepsis or other critical illness. Critically ill patients who do not have evidence of
renal insufficiency or decreased urine output will develop a diuresis in response to dopamine
at 2 to 3 mcg/kg per minute, with variable effects on creatinine clearance, but the benefit of
this diuresis is questionable [12,25]. The intervention is not entirely benign because
hypotension and tachycardia may ensue. One small study demonstrated that the addition of
low dose dopamine to patients receiving other vasopressors increases splanchnic blood flow
but does not alter other indices of mesenteric perfusion, such as gastric intramucosal pH
(pHi) [66].

At present, there are no data to support the routine use of low dose dopamine to prevent or
treat acute renal failure or mesenteric ischemia. In general, the most effective means of
protecting the kidneys in the setting of septic shock appears to be the maintenance of mean
arterial pressure (MAP) >60 mmHg while attempting to avoid excessive vasoconstriction (ie,
the systemic vascular resistance [SVR] should not exceed 1300 dynes x sec/cm5) [7,14,67,68].

Optimal dosage — Although norepinephrine doses of up to 100 mcg/min in adults are

typically used in refractory shock and as salvage therapy in combination with a second
vasopressor agent, there is no well-established maximum dose. Several studies have
suggested improved tissue perfusion when higher doses of norepinephrine (up to 350
mcg/min) are used [14,68] but no survival benefit of high-dose norepinephrine has been
conclusively proven.
Supranormal cardiac index — Elevation of the cardiac index with inotropic agents to
supranormal values (ie, >4.5 L/minute per m2) potentially increases oxygen delivery to
peripheral tissues. In theory, increased oxygen delivery may prevent tissue hypoxia and
improve outcomes, and initial studies appeared to support this hypothesis [69-71]. However,
later larger trials showed that goal-oriented hemodynamic therapy to increase either cardiac
index to >4.5 L/min per m2 or oxygen delivery to >600 to 650 mL/min per m2 with volume
expansion or dobutamine resulted in either no improvement or worsened morbidity or
mortality [15,16,72]. Therefore, the routine administration of vasopressors or inotropes to
improve cardiac output or oxygen delivery to supranormal levels is not advocated. (See
"Oxygen delivery and consumption".)

The American Thoracic Society (ATS) statement on the detection, correction, and prevention
of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site
at www.thoracic.org/statements.

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Sepsis in children
and adults".)

SUMMARY AND RECOMMENDATIONS

● Definition – Vasopressors are a powerful class of drugs that induce vasoconstriction

and elevate mean arterial pressure (MAP). (See 'Introduction' above.)

● Physiology – Alpha-1 adrenergic receptors induce vasoconstriction, while beta-1

receptors induce inotropy plus chronotropy, and beta-2 receptors induce vasodilation.
One subtype of dopamine receptor induces norepinephrine release with subsequent
vasoconstriction, although many dopamine receptors induce vasodilation. Some agents
increase the sensitivity of the myocardial contractile apparatus to calcium while others
cause direct vasoconstriction via angiotensin II receptor stimulation. (See 'Physiologic
mechanisms of vasoconstriction' above.)

● Principles – Vasopressors are indicated for an MAP <60 mmHg, or a decrease of

systolic blood pressure that exceeds 30 mmHg from baseline, when either condition
results in end-organ dysfunction due to hypoperfusion. (See 'Principles' above.)

● Practical issues – Hypovolemia should be corrected prior to the institution of

vasopressor therapy for maximum efficacy. Patients should be re-evaluated frequently
 once vasopressor therapy has been initiated. Common issues that arise include
tachyphylaxis, which may require dose titration, and additional hemodynamic insults,
which should be recognized and managed. (See 'Practical issues' above.)

● Choosing an agent – Choice of an initial agent should be based upon the suspected
underlying etiology of shock (eg, dobutamine for cardiogenic shock without significant
hypotension, norepinephrine for septic and cardiogenic shock with hypotension,
epinephrine for anaphylactic shock). (See 'Practical issues' above and "Prognosis and
treatment of cardiogenic shock complicating acute myocardial infarction", section on
'Vasopressors and inotropes'.)

● Complications – Complications of vasopressor therapy include hypoperfusion

(particularly affecting the extremities, mesentery or kidneys), dysrhythmias, myocardial
ischemia, peripheral extravasation with skin necrosis, and hyperglycemia. (See
'Complications' above.)

Use of UpToDate is subject to the Terms of Use.

REFERENCES

1. Müllner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst
Rev 2004; :CD003709.

2. AHLQUIST RP. A study of the adrenotropic receptors. Am J Physiol 1948; 153:586.

3. ALLWOOD MJ, COBBOLD AF, GINSBURG J. Peripheral vascular effects of noradrenaline,
isopropylnoradrenaline and dopamine. Br Med Bull 1963; 19:132.

4. Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive
inotropic actions of phenylephrine in rat cardiac muscle. Am J Physiol 1994; 266:H2462.

5. Catt KJ, Mendelsohn FA, Millan MA, Aguilera G. The role of angiotensin II receptors in
vascular regulation. J Cardiovasc Pharmacol 1984; 6 Suppl 4:S575.

6. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task
Force of the American College of Critical Care Medicine, Society of Critical Care Medicine.
Crit Care Med 1999; 27:639.

7. Moran JL, O'Fathartaigh MS, Peisach AR, et al. Epinephrine as an inotropic agent in
septic shock: a dose-profile analysis. Crit Care Med 1993; 21:70.

8. Calvin JE, Driedger AA, Sibbald WJ. Does the pulmonary capillary wedge pressure predict
left ventricular preload in critically ill patients? Crit Care Med 1981; 9:437.
9. Packman MI, Rackow EC. Optimum left heart filling pressure during fluid resuscitation of
patients with hypovolemic and septic shock. Crit Care Med 1983; 11:165.
10. Datar S, Gutierrez E, Schertz A, Vachharajani V. Safety of Phenylephrine Infusion
Through Peripheral Intravenous Catheter in the Neurological Intensive Care Unit. J
Intensive Care Med 2018; 33:589.
11. Ballieu P, Besharatian Y, Ansari S. Safety and Feasibility of Phenylephrine Administration
Through a Peripheral Intravenous Catheter in a Neurocritical Care Unit. J Intensive Care
Med 2021; 36:101.

12. Lherm T, Troché G, Rossignol M, et al. Renal effects of low-dose dopamine in patients
with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med
1996; 22:213.
13. Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour
continuous infusion. Am J Med 1980; 69:262.

14. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of
hyperdynamic septic shock? Chest 1993; 103:1826.

15. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in

critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025.

16. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the
treatment of critically ill patients. N Engl J Med 1994; 330:1717.
17. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-
molecular-weight heparin to patients on vasopressors. Lancet 2002; 359:849.

18. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component
of the pharmacologic support of septic shock. Crit Care Med 1991; 19:1395.

19. Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with

phenylephrine in hyperdynamic sepsis. Crit Care Med 1982; 10:432.

20. De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and
epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med
2003; 31:1659.

21. MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy
male subjects. Anesthesiology 2000; 92:338.
22. Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med
1974; 291:707.

23. HORWITZ D, FOX SM 3D, GOLDBERG LI. Effects of Dopamine in man. Circ Res 1962;
10:237.

24. Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine.
Pharmacotherapy 1986; 6:304.

25. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose
dopamine or low-dose dobutamine? Crit Care Med 1994; 22:1919.
26. Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med 1990;
18:S56.

27. Steel, A, Bihari, D . Choice of catecholamine: does it matter? Curr Opin Crit Care 2000;
6:347.

28. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine

and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995;
23:1962.

29. Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac
sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 2002;
39:1269.

30. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in

the treatment of shock. N Engl J Med 2010; 362:779.
31. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive
Care Med 2004; 30:1276.

32. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock.
Crit Care Med 2003; 31:1752.

33. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-
dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487.

34. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory
shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313.

35. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with
vasopressin. Two case reports. Int Arch Allergy Immunol 2004; 134:260.

36. Schummer C, Wirsing M, Schummer W. The pivotal role of vasopressin in refractory

anaphylactic shock. Anesth Analg 2008; 107:620.
37. McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine
Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With
Distributive Shock: A Systematic Review and Meta-analysis. JAMA 2018; 319:1889.

38. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in

hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005;
33:1897.

39. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its
clinical relevance. Anaesthesia 2004; 59:993.

40. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock.

Lancet 2002; 359:1209.

41. Leone M, Albanèse J, Delmas A, et al. Terlipressin in catecholamine-resistant septic

shock patients. Shock 2004; 22:314.
42. Rodríguez-Núñez A, Fernández-Sanmartín M, Martinón-Torres F, et al. Terlipressin for
catecholamine-resistant septic shock in children. Intensive Care Med 2004; 30:477.

43. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional
haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med
2004; 30:597.
44. Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an
ESICM systematic review and meta-analysis. Intensive Care Med 2012; 38:9.

45. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs
Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH
Randomized Clinical Trial. JAMA 2016; 316:509.
46. Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin
doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.
Intensive Care Med 2010; 36:57.

47. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of
vasopressin in septic shock. Crit Care Med 2004; 32:1327.

48. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin
administered for septic shock. Crit Care Med 2002; 30:1899.

49. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular
function in an experimental model of acute pulmonary hypertension. Crit Care Med
2002; 30:2548.

50. Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous
vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk
factors. Crit Care Med 2003; 31:1394.
51. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in
patients with septic shock. N Engl J Med 2008; 358:877.

52. Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the
discontinuation order of vasopressors in the management of septic shock: a prospective
randomized trial (DOVSS). Crit Care 2018; 22:131.

53. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International

Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;
49:e1063.

54. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans
with septic shock. Cardiovasc Res 1994; 28:34.

55. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support
after Cardiac Surgery. N Engl J Med 2017.
56. Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in Patients with Left
Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med 2017.
57. Antonucci E, Gleeson PJ, Annoni F, et al. Angiotensin II in Refractory Septic Shock. Shock
2017; 47:560.

58. Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment
of high-output shock (ATHOS trial): a pilot study. Crit Care 2014; 18:534.

59. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory
Shock. N Engl J Med 2017; 377:419.

60. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on
systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;
272:1354.

61. Bohr DF. Adrenergic receptors in coronary arteries. Ann N Y Acad Sci 1967; 139:799.
62. Peters, JI, Utset, OM. Vasopressors in shock management: Choosing and using wisely. J
Crit Illness 1989; 4:62.

63. Hollenberg NK, Adams DF, Mendell P, et al. Renal vascular responses to dopamine:
haemodynamic and angiographic observations in normal man. Clin Sci Mol Med 1973;
45:733.

64. D'Orio V, el Allaf D, Juchmès J, Marcelle R. The use of low doses of dopamine in intensive
care medicine. Arch Int Physiol Biochim 1984; 92:S11.

65. Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus low-
dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care
Med 1985; 13:492.

66. Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine on
splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care
Med 1997; 23:31.

67. Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock
with norepinephrine therapy. Crit Care Med 1988; 16:663.
68. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on
hemodynamics and renal function in severe septic shock states. Intensive Care Med
1993; 19:151.

69. Shoemaker WC, Kram HB, Appel PL. Therapy of shock based on pathophysiology,
monitoring, and outcome prediction. Crit Care Med 1990; 18:S19.

70. Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to
management of the critically ill. Am J Respir Crit Care Med 1994; 149:533.

71. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen
delivery improves outcome in septic shock. Chest 1992; 102:216.
 72. Alía I, Esteban A, Gordo F, et al. A randomized and controlled trial of the effect of
treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic
shock. Chest 1999; 115:453.
Topic 1619 Version 40.0
GRAPHICS

Vasopressors and inotropes in treatment of acute hypotensive states and

shock: Adult dose and selected characteristics

United Range of
Usual
States maximum doses
Agent Initial dose maintenance
trade used in
dose range
name refractory shock

Vasopressors (alpha-1 adrenergic)

Norepinephrine Levophed 5 to 15 mcg/minute 2 to 80 mcg/minute 80 to

(noradrenaline) (0.05 to (0.025 to 250 mcg/minute (1
0.15 mcg/kg/minute) 1 mcg/kg/minute) to
3.3 mcg/kg/minute)
Cardiogenic shock: Cardiogenic shock:
0.05 mcg/kg/minute 0.05 to
0.4 mcg/kg/minute

Epinephrine Adrenalin 1 to 15 mcg/minute 1 to 40 mcg/minute 40 to

(adrenaline) (0.01 to (0.01 to 160 mcg/minute
0.2 mcg/kg/minute) 0.5 mcg/kg/minute) (0.5 to
2 mcg/kg/minute)
Phenylephrine Neo- 40 to 20 to 80 to
Synephrine, 160 mcg/minute 400 mcg/minute 730 mcg/minute
Vazculep until stabilized (0.25 to (1.1 to
(alternatively, 0.5 to 5 mcg/kg/minute) 9.1 mcg/kg/minute)
2 mcg/kg/minute)
Dopamine Inotropin 2 to 2 to 20 mcg/kg/minute
5 mcg/kg/minute 20 mcg/kg/minute
Antidiuretic hormone

Vasopressin Pitressin, 0.03 units/minute 0.01 to Doses

(arginine- Vasostrict 0.04 units/minute >0.04 units/minute
vasopressin) (not titrated) can cause cardiac
ischemia and
should be reserved
for salvage therapy

Inotrope (beta1 adrenergic)

Dobutamine Dobutrex Usual: 2 to 2 to 20 mcg/kg/minute

5 mcg/kg/minute 10 mcg/kg/minute
(range: 0.5 to
5 mcg/kg/minute;
lower doses for less
severe cardiac
decompensation)
Inotrope (nonadrenergic, PDE3 inhibitor)

Milrinone Primacor 0.125 to 0.125 to 0.75 mcg/kg/minute

0.25 mcg/kg/minute 0.75 mcg/kg/minute
 All doses shown are for intravenous (IV) administration in adult patients. The initial doses shown in
this table may differ from those recommended in immediate post-cardiac arrest management (ie,
advanced cardiac life support). For details, refer to the UpToDate topic review of post-cardiac arrest
management in adults, section on hemodynamic considerations.
Vasopressors can cause life-threatening hypotension and hypertension, dysrhythmias, and
myocardial ischemia. They should be administered by use of an infusion pump adjusted by
clinicians trained and experienced in dose titration of intravenous vasopressors using continuous
noninvasive electronic monitoring of blood pressure, heart rate, rhythm, and function.
Hypovolemia should be corrected prior to the institution of vasopressor therapy. Reduce infusion
rate gradually; avoid sudden discontinuation.
Vasopressors can cause severe local tissue ischemia; central line administration is preferred. When
a patient does not have a central venous catheter, vasopressors can be temporarily administered
in a low concentration through an appropriately positioned peripheral venous catheter (ie, in a
large vein) for less than 24 hours. The examples of concentrations shown in this table are useful
for peripheral (short-term) or central line administration. Closely monitor catheter site throughout
infusion to avoid extravasation injury. In event of extravasation, prompt local infiltration of an
antidote (eg, phentolamine) may be useful for limiting tissue ischemia. Stop infusion and refer to
extravasation management protocol.
Vasopressor infusions are high-risk medications requiring caution to prevent a medication error
and patient harm. To reduce the risk of making a medication error, we suggest that centers have
available protocols that include steps on how to prepare and administer vasopressor infusions
using a limited number of standardized concentrations. Examples of concentrations and other
detail are based on recommendations used at experienced centers; protocols can vary by
institution.

D5W: 5% dextrose water; MAP: mean arterial pressure; NS: 0.9% saline.

Prepared with data from:

1. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis
and septic shock: 2016. Crit Care Med 2017; 45:486.
2. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183:847.
3. Lexicomp Online. Copyright © 1978-2022 Lexicomp, Inc. All Rights Reserved.

Graphic 99963 Version 20.0

Vasoactive medication receptor activity and clinical effects

Receptor activity
Drug Alpha- Beta- Beta-
Predominant clinical effects
Dopaminergic
1 1 2

Phenylephrine +++ 0 0 0 SVR ↑ ↑, CO ↔/↑

Norepinephrine +++ ++ 0 0 SVR ↑ ↑, CO ↔/↑

Epinephrine +++ +++ ++ 0 CO ↑ ↑, SVR ↓ (low dose) SVR/↑

(higher dose)

Dopamine (mcg/kg/min)*

0.5 to 2. 0 + 0 ++ CO

5. to 10. + ++ 0 ++ CO ↑, SVR ↑

10. to 20. ++ ++ 0 ++ SVR ↑ ↑

Dobutamine 0/+ +++ ++ 0 CO ↑, SVR ↓

Isoproterenol 0 +++ +++ 0 CO ↑, SVR ↓

+++: Very strong effect; ++: Moderate effect; +: Weak effect; 0: No effect; SVR: systemic vascular
resistance; CO: cardiac output.

* Doses between 2. and 5. mcg/kg/min have variable effects.

Graphic 63100 Version 2.0

Contributor Disclosures
Scott Manaker, MD, PhD Other Financial Interest: National Board for Respiratory Care [Director];
Expert witness in workers' compensation and in medical negligence matters [General pulmonary and
critical care medicine]. All of the relevant financial relationships listed have been mitigated. Polly E
Parsons, MD No relevant financial relationship(s) with ineligible companies to disclose. Geraldine
Finlay, MD No relevant financial relationship(s) with ineligible companies to disclose.

El grupo editorial revisa las divulgaciones de los contribuyentes en busca de conflictos de intereses.
Cuando se encuentran, estos se abordan mediante la investigación a través de un proceso de revisión
de múltiples niveles y mediante los requisitos para que se proporcionen referencias para respaldar el
contenido. Se requiere que todos los autores tengan contenido referenciado de manera adecuada y
debe cumplir con los estándares de evidencia de UpToDate.

Política de conflicto de intereses